Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03393741 · ClinicalTrials.gov registry record
Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy
A clinical trial, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- 5
- Enrollment target
NCT03393741 is a clinical trial that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 5 participants.
The verdict
NCT03393741 was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- 5 participants
- Enrollment target
Study Summary
Eligible subjects will be assigned to study treatment arms by their treating oncologist, rather than by the study. The drug, dose, and schedule of administration will be determined by the treating physician per NCCN guidelines for standard of care chemotherapy regimens for recurrent or metastatic breast cancer. Study treatment arms include: Taxane (nab-paclitaxel or paclitaxel), Eribulin, Vinorelbine, Ixabepilone, or the control arm (non-microtubule targeted chemotherapies such as doxorubicin, carboplatin, or gemcitabine).
Interventions
- DRUG Chemotherapy
- DRUG Eribulin
- DRUG Vinorelbine
- DRUG Taxane
- DRUG Ixabepilone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2018-01-29 |
| Est. Completion | 2024-02-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03393741
The ClinicalTrials.gov registry entry for NCT03393741 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Chemotherapy is the first listed.
NCT03393741 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03393741 about?
NCT03393741 is a clinical study titled "Pharmacodynamic Biomarkers of Standard Anti-microtubule Drugs as Assessed by Early Tumor Biopsy". Eligible subjects will be assigned to study treatment arms by their treating oncologist, rather than by the study. The drug, dose, and schedule of administration will be determined by the treating physician per NCCN guidelines for standard of care chemotherapy regimens for recurrent or metastatic br...
What is the current status of trial NCT03393741?
This trial is currently terminated. The enrollment target is 5 participants. The study started on 2018-01-29. Estimated completion is 2024-02-11.
What interventions are being tested in trial NCT03393741?
The interventions under investigation include: Chemotherapy (DRUG), Eribulin (DRUG), Vinorelbine (DRUG), Taxane (DRUG), Ixabepilone (DRUG).
Who is sponsoring clinical trial NCT03393741?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.